Floatz logo

Omnipaque

TNBC, Triple Negative Breast Cancer

Alison StopeckEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the TNBC, Triple Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Iparomlimab
Jiangsu Cancer Institute & Hospital
Phase 2B
Theprubicin
Xijing Hospital
Phase 2B
Fluzoparib
Tianjin Medical University Cancer Institute and Hospital
Phase 2CCC
177lu-betabart
Radiopharm Theranostics, Ltd
Phase 1/2CC
177lu-rad204
Radiopharm Theranostics, Ltd
Early Phase 1C

Same molecule, other indications

Omnipaque is also rated in:

Adolescent ObesityDormant
CCC
Indicative ·
52 / 100
View asset →
Diabetic Kidney DiseaseDormant
CCC
Indicative ·
52 / 100
View asset →
Diabetes ComplicationsDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →